References
1. Schulte, T.W. and Neckers, L.M. "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin." Cancer Chemother. Pharmacol. 42:273-279 (1998). 2. Basso, A.D., et al. "Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2." Oncogene 21:1159-1166 (2002). 3. Kamal, A., et al. "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors." Nature 425:407-10 (2003). 4. Nguyen, D.M., et al. "Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin." J. Thorac. Cardiovasc. Surg. 118:908-915 (1999) 5. Solit, D.B., et al. "Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol." Cancer Res. 63:2139-2144 (2003). 6. Vasilevskaya, I.A., et al. "Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines." Mol Pharmacol. 65:235-243 (2004). 7. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10:4813-4821 (2004).USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
